|
TOP
|
|
vidaza(azacitidine)injection, powder, lyophilized, for suspe(八)
|
ll patients exposed to Vidaza, including patients after crossing over from observation.
|
|
Nausea |
155 (70.5) |
16 (17.4) |
|
Anemia |
153 (69.5) |
59 (64.1) |
|
Thrombocytopenia |
144 (65.5) |
42 (45.7) |
|
Vomiting |
119 (54.1) |
5 (5.4) |
|
Pyrexia |
114 (51.8) |
28 (30.4) |
|
Leukopenia |
106 (48.2) |
27 (29.3) |
|
Diarrhea |
80 (36.4) |
13 (14.1) |
|
Fatigue |
79 (35.9) |
23 (25.0) |
|
Injection site erythema |
77 (35.0) |
0 |
|
Constipation |
74 (33.6) |
6 (6.5) |
|
Neutropenia |
71 (32.3) |
10 (10.9) |
|
Ecchymosis |
67 (30.5) |
14 (15.2) |
|
Cough |
65 (29.5) |
14 (15.2) |
|
Dyspnea |
64 (29.1) |
11 (12.0) |
|
Weakness |
64 (29.1) |
19 (20.7) |
|
Rigors |
56 (25.5) |
10 (10.9) |
|
Petechiae |
52 (23.6) |
8 (8.7) |
|
Injection site pain |
50 (22.7) |
0 |
|
Arthralgia |
49 (22.3) |
3 (3.3) |
|
Headache |
48 (21.8) |
10 (10.9) |
|
Anorexia |
45 (20.5) |
6 (6.5) |
|
Pain in limb |
44 (20.0) |
5 (5.4) |
|
Pharyngitis |
44 (20.0) |
7 (7.6) |
|
Back pain |
41 (18.6) |
7 (7.6) |
|
Contusion |
41 (18.6) |
9 (9.8) |
|
Dizziness |
41 (18.6) |
5 (5.4) |
|
Edema peripheral |
41 (18.6) |
10 (10.9) |
|
Erythema |
37 (16.8) |
4 (4.3) |
|
Chest pain |
36 (16.4) |
5 (5.4) |
|
Epistaxis |
36 (16.4) |
9 (9.8) |
|
Febrile neutropenia |
36 (16.4) |
4 (4.3) |
|
Myalgia |
35 (15.9) |
2 (2.2) |
|
Weight decreased |
35 (15.9) |
10 (10.9) |
|
Abdominal pain |
34 (15.5) |
12 (13.0) |
|
Pallor |
34 (15.5) |
7 (7.6) |
|
Nasopharyngitis |
32 (14.5) |
3 (3.3) |
|
Pitting edema |
32 (14.5) |
9 (9.8) |
|
Skin lesion |
32 (14.5) |
8 (8.7) |
|
Dyspnea exertional |
31 (14.1) |
15 (16.3) |
|
Injection site bruising |
31 (14.1) |
0 |
|
Rash |
31 (14.1) |
9 (9.8) |
|
Injection site reaction |
30 (13.6) |
0 |
|
Anxiety |
29 (13.2) |
3 (3.3) |
|
Appetite decreased |
28 (12.7) |
8 (8.7) |
|
